Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026
Rein Therapeutics, Inc. (RNTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $6.4 million.
Revenue
$0
Net income
$-6.38M
+6.6% vs year-ago quarter
Operating cash flow
$-8.64M
-34.6% vs year-ago quarter
Free cash flow
—
EPS
$-0.10
+64.3% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
86.27M
+270.2% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$6.1M | -$5.2M | -$32.7M | -$5.5M | -$6.9M |
| Net income | -$6.4M | -$5.8M | -$32.0M | -$5.6M | -$6.8M |
| Diluted EPS | -$0.10 | -$0.19 | -$1.09 | -$0.21 | -$0.28 |
| Operating cash flow | -$8.6M | -$3.4M | -$3.2M | -$3.5M | -$6.4M |
| Total assets | $66.0M | $26.3M | $24.2M | $53.7M | $57.5M |
| Total liabilities | $10.8M | $14.7M | $7.2M | $7.5M | $9.5M |
| Stockholders' equity | $55.2M | $11.6M | $16.9M | $46.2M | $48.0M |
| Cash and investments | $43.6M | $4.4M | $3.2M | $4.0M | $5.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 27, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 21, 2026 | Jul 20, 2026 |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 525 Rein Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.